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ABSTRACT
Matrix metalloproteinases (MMPs), are a family of structurally related zinc
containing enzymes that play a major role in the breakdown of connective tissue
and therefore, are targets for therapeutic inhibitors in many inflammatory,
malignant, and degenerative diseases. On the other hand, it has been recently
demonstrated that one of these enzymes, MMP-2, a type IV collagenase, termed
gelatinase A, cleaves the angiogenic peptide adrenomedullin (AM) (1). AM is a
peptide hormone that plays a critical role in several diseases such as diabetes,
hypertension and cancer. In a High Throughput Screening (HTS) carried out at the
National Cancer Institute (NCI), a series of AM modulators were identified, with an
interesting hypotensive activity (2). In order to shed light into the mechanism of
action of these interesting compounds, we have hypothesized that they may be
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affecting the biodisponibility of AM in the blood stream by inhibiting the MMP-2
protease activity. In the present work, we present a theoretical study, making use
of molecular mechanics, docking and virtual screening techniques, with the aim of
demonstrating this hypothesis. Biological evaluation of MMP-2 inhibition by some
selected compounds, followed the computational work, leading us to propose a
structurally new type of MMP-2 inhibitors, with possible interest as anticancer and
antiangiogenic agents.
Key words: Zinc-binding-group (ZBG).—Docking.—Virtual screening.
RESUMEN
¿Son los moduladores positivos de adrenomedulina nuevos inhibidores
de metaloproteasas de la matriz?
Las metaloproteasas de la matriz (MMPs) pertenecen a la familia de enzimas
que contienen zinc y juegan un papel predominante en la degradación del tejido
conectivo. Por ello se consideran dianas terapéuticas para procesos de inflamación
y enfermedades malignas y degenerativas. Por otro lado, se ha demostrado reciente-
mente que un miembro de esta familia, MMP-2, una colagenasa de tipo IV también
conocida como gelatinasa A, es capaz de degradar un péptido angiogénico denomi-
nado adrenomedulina (AM) (1). AM es una hormona peptídica que desarrolla un
papel importante en diversas patologías como diabetes, hipertensión y cáncer. Se
ha identificado mediante un cribado de alto rendimiento (HTS) de la colección de
compuestos del Instituto Nacional del Cáncer (NCI), una serie de moduladores con
interesante actividad hipotensora (2). El mecanismo de acción de estos modulado-
res es desconocido y nosotros proponemos que pueden afectar a la biodisponibili-
dad de la AM en el torrente sanguíneo por medio de la inhibición de la actividad de
la MMP-2. En este trabajo presentamos un estudio teórico que hace uso de técnicas
como mecánica molecular, docking y Cribado Virtual con el objetivo de demostrar
esa hipótesis. A continuación del estudio computacional se llevó a cabo la evalua-
ción biológica de algunos compuestos, permitiéndonos proponer un nuevo tipo de
ZBG que puede ser interesante para el diseño de nuevos inhibidores de MMPS, con
interés como agentes anticancerosos y antiangiogénicos.
Palabras clave: Grupo de unión al zinc.—Docking.—Cribado virtual.
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INTRODUCTION
Matrix Metalloproteinases Classification
Matrix metalloproteinases (MMPs), also called matrixins, are a
family of structurally related zinc-containing enzymes that mediate
the breakdown of connective tissue and are therefore targets for
therapeutic inhibitors in many inflammatory, malignant, and
degenerative diseases (3).
The mammalian MMP family is now known to include at
least 24 enzymes. The most studied are three collagenases:
interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8),
and collagenase-3 (MMP-13). These enzymes can degrade the
fibrillar collagens, which are generally resistant to proteolysis.
The MMP family also includes two type IV collagenases, termed
gelatinase A (MMP-2) and gelatinase B (MMP-9), which can
degrade type IV collagen of basal laminae, as well as other non
helical collagen domains and proteins, such as fibronectin and
laminin. Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10)
degrade various proteoglycan components of the extracellular matrix
as well as fibronectin and laminin.
Several subsites have been described (S1, S2, S3, S1’, S2’, and
S3’) being responsible for different roles affecting activity
and selectivity, depending on the MMP considered (4). These
requirements can be satisfied by a variety of different structural
classes of MMP inhibitors (MMPIs), which have been discovered by
a number of methods, including structure-based design (5, 6) and
combinatorial chemistry (7).
Proteolytic Reaction Mechanism
The proteolytic reaction of MMPs has been rationalized on the
basis of structural information (Figure 1) (8). It has been proposed
that the scissile amide carbonyl coordinates to the active site
Zn2+ ion. This carbonyl is attacked by a water molecule that is
simultaneously hydrogen bonded to a conserved glutamic acid
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(Glu198 in MMP-8) and coordinated to the Zn2+ ion. The water
donates a proton to the Glu residue that transfers it to the nitrogen
of the scissile amide. This is followed by the Glu residue shuttling
the remaining proton from the water molecule to the nitrogen of the
scissile amide with resultant peptide bond cleavage. During this
process, the positively charged Zn2+ ion helps to stabilize negative
charge at the carbon of the scissile amide and a conserved Ala
(Ala161 in MMP-8) residue helps to stabilize the positive charge at
the nitrogen of the scissile amide.
FIGURE 1. Mechanism of proteolysis carried out by MMPs, as reported by
Lovejoy et al.
Biological Implications of MMPs
Matrix metalloproteinases are responsible of remodelling and
degrading extracellular matrix, and are implicated in a wide variety
of biological processes such as embryonic development, blastocyst
implantation, nerve growth, ovulation, morphogenesis, angiogenesis,
tissue resorption and remodelling, bone remodelling, apoptosis,
cancer invasion and metastasis, arthritis (osteo- and rheumatoid-),
atherosclerotic plaque rupturing, pulmonary emphysema, aortic
aneurysms, breakdown of blood-brain barrier, periodontal disease,
skin ulceration, corneal ulceration, gastric ulcer, multiple sclerosis,
Crohn’s disease, psoriasis, dermatitis, congestive heart failure and
Alzheimer’s disease (9).
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Matrix Metalloproteinases Inhibitors (MMPIs)
Many groups of compounds are used as MMPs inhibitors. The
requirements for a molecule to be an effective MMP inhibitor are:
a) a functional group (e.g. carboxylic acid, hydroxamic acid,
sulfhydryl, etc.) capable of chelating the catalytic Zn2+ ion (this will be
referred as zinc binding group or ZBG); b) at least one functional
group which provides a hydrogen bond interaction with the enzyme
backbone; and c) one or more side chains that undergo effective van
der Waals interactions with the enzyme subsites. These requirements
can be satisfied by a variety of different structural classes of MMP
inhibitors, which have been discovered by a number of methods,
including structure-based design (5) and combinatorial chemistry (7).
Zn2+-chelating hydroxamates have been the most frequently used
ZBG in MMPI design, because of their higher ΔG values, but as
shown below, a number of other groups are possible. However,
strong Zn2+-chelating moieties disproportionately drive binding mode
and make the contributions from the rest of the compound smaller,
reducing other opportunities for improved specificity. Indeed, it
has been demonstrated that some hydroxamate derivatives bind
many off-target metalloproteinases (MPs) that are not MMPs (10).
This may be related to the lack of selectivity of hydroxamic acid
for zinc over other divalent transition metals. The use of weaker
zinc chelating groups would reduce the strength of zinc binding,
and the optimization on the rest of the molecule should lead to
nanomolar inhibitors. This means, that the design of MMPIs should
be addressed individually in order to achieve selectivity.
The reported types of MMPIs include hydroxamates (succinyl
hydroxamates, sulfonamide hydroxamates, reverse hydroxamates,
naphthyl hydroxamates), non-hydroxamates (carboxylates and N-
carboxyalkyl ZBGs, thiol ZBGs, phosphorus-based ZBGs), and
miscellaneous natural products (7, 11).
Novel Zinc Binding Groups
In spite of the time and the money invested, and the numerous
groups interested on the development of MMPIs based on the
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described ZBGs (Table 1 summarises the most important ZBGs
described in the literature), no MMPI has been licensed for treatment
of cancer until date. This is mainly due to low activity, low selectivity,
high toxicity, low bioavailability and/or low solubility. Only one
MMPI, PeriostatTM (CollaGenex Pharmaceuticals, Inc.), a low-dose
tetracycline derivative, is licensed for use in periodontitis and it is
under clinical trials for other indications (12). Thus, research focused
on the search of new ZBG becomes necessary.
TABLE 1. Summary of the most important Zinc Binding Groups (ZBGs) described
in the literature (11). Atoms implicated in zinc coordination are displayed in bold
format. ZBGs with unknown binding mode are displayed without bold atoms
Name Representative Name Representative
Structure Structure
Hydroxamate
Carboxylate
Thiol carbonyl
Phosphate
Carbamoyl
Phosphonate
Hydrazide
Barbiturate
Reverse
Hydroxamate
Thiol
Dithiol
Phosphinate
Tetracycline
Thiirane
Thiadiazine
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TABLE 1. Summary of the most important Zinc Binding Groups (ZBGs) described
in the literature (11). Atoms implicated in zinc coordination are displayed in bold
format. ZBGs with unknown binding mode are displayed without bold atoms (cont.)
Name Representative Name Representative
Structure Structure
Thiadiazole
thione
Pyridone and
Pyridinetione
Pyrimidin-
carbonil
Aminomethyl
benzimidazole
Pirrol carbonyl
Dipicolylamine
Squaric Acid
(X=O, S)
Sulfodiimine
Hydroxipiranone
and
Hydroxipiranthinone
N-pyrimidin-amide
Hydroxysulfonamide
Hydroxyurea
β-Lactam
Several new ZBGs have been recently described (11). The
hydrazide scaffold has also been described as a good ZBG, and
exhibits potent selectivity for MMP-2 versus MMP-1. Brown et al.
described a novel ZBG based on a thiirane moiety, which behaves
similarly to TIMP-1 and TIMP-2, the natural tissue inhibitors of
MMPs (13). Barbiturates have also been cocrystalized (PDB code:
1g4k) in complex with MMP-3 but no information on the activity as
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MMPI has been reported to date. A selective inhibitor of MMP-9 has
been obtained using a thiadiazine scaffold, and a similar ZBG, the
thiadiazole thione, has been analyzed in the catalytic site of MMP-
3. Browner et al. investigated the differences among three identical
compounds bearing different ZBGs (hydroxamate, carboxylate and
sulfodiimines, crystalized in complex with MMP-7), concluding that
the binding potency differences among them were consequence of
the geometry adopted by the ZBG chelating the zinc atom (14).
Another theoretical study showed that pyridone analogues can
behave as ZBGs as well. Also, the aminomethyl benzimidazole group
has been described as a ZBG with micromolar activity.
Others ZBGs not described by Rao et al. include
hydroxysulfonamides (15), hydroxyureas (16), dipicolylamines
(17), β-lactams (18) and squaric acids (18). Additionally, 3D
structures of many MMP-Inhibitor complexes, solved either by X-
ray diffraction or NMR techniques, have shown that the different
chelating ZBGs coordinate catalytic zinc ion most frequently in a
pentacoordinated way (19).
Binding of MMPIs is not only explained by coordination of the
ligand ZBG to the catalytic zinc ion. Binding and, more importantly,
selectivity, have been addressed by interactions with key residues
belonging to different subsites, specially the S1’ region. Thus,
extensive hydrophobic interactions between the lipophilic moieties
of the ligands and the S1’ pocket can be largely responsible for the
binding potencies (20).
Since a combination of factors, including the nature of ZBG,
scaffolds and side chains that occupy different subsites, influence
the selectivity and that the structural differences between MMPs
take place mainly in the S1’ sub-site, all these features will have to
be taken into account in order to design compounds with the desired
selectivity.
Working Hypothesis: Can AM positive modulators be MMP2
inhibitors?
Matrix metalloproteinases are responsible of degrading several
components of the extracellular matrix (ECM), among other proteins
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and peptides of the extracellular medium as mentioned before.
Adrenomedullin (AM), a 52 amino acid peptide isolated from a
human pheochromocytoma (adrenal tumour) (21), is an interesting
example of MMP substrate. Martínez et al., have reported how the
adrenomedullin is cleaved by MMP-2 (1). Interestingly they also
report that AM is not cleaved by MMP-9, so MMP-2 may be
considerered as a specific protease of AM.
Our group has identified by a HTS a series of compounds that
modulate the activity of adrenomedullin (Table 2) (22). These
compounds have demonstrated to increase the production of cAMP,
the second messenger released upon binding of AM to its receptor,
but, interestingly, only in presence of the AM peptide. Furthermore,
they are able to bind to AM but there is no direct relationship between
the affinity to AM and the amount of cAMP production. These facts
led us to the hypothesis that the mechanism of action of these
compounds may involve affecting the availability of AM. That is,
modulators of AM could inhibit the MMP-2 protease activity, so, the
AM levels would be increased and consequently the cAMP production
would be elevated. This work tries to shed light into the possibility
that AM modulators and some derivatives could act as matrix
metalloproteinases inhibitors. This hypothesis could drive, not only
to an explanation of the mechanism of action of the modulators, but
also to the discovery of novel ZBGs which could be exploited for the
design of potent and selective inhibitors for MMP-2.
TABLE 2. Positive AM modulators and related compounds, that were used in the
computational study
Series 1 Series 2 Series 3
compd n R R’ compd n compd N
1a 8 Ph NH-Ph 2j 4 3j 4
1b 8 p-Cl-phenyl NH2 2k 5 3k 5
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TABLE 2. Positive AM modulators and related compounds, that were used in the
computational study (cont.)
Series 1 Series 2 Series 3
compd n R R’ compd n compd N
1c 8 o, p-diCl-
phenyl NH2 2l 6 3l 6
1d 8 1-hydroxi-2-
naphtyl NH2 2m 7 3m 7
1e 8 2-hydroxi-1-
naphtyl NH2 2n 8 3n 8
1f 8 p-Cl-phenyl NH-Ph
1g 8 o, p-diCl-
phenyl NH-Ph
1h 8 1-hydroxi-2-
naphtyl NH-Ph
1i 8 2-hydroxi-1-
naphtyl NH-Ph
1j 4 Ph CH2Ph
1k 5 Ph CH2Ph
1l 6 Ph CH2Ph
1m 7 Ph CH2Ph
1n 8 Ph CH2Ph
MATERIALS AND METHODS
Macromolecule Selection
The 3D superimposition of the eleven different models of the
1hov against 1ck7 and 1qib (see Table 3) was carried out using
Sybyl7.2 (23).
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All models were selected for docking procedures. For docking
purposes, the protonation state of histidines and glutamates in the
binding site was maintained as it was in the NMR structure. Both
zinc and calcium heteroatoms were kept throughout the docking
study.
Ligand Processing
All the ligands (series 1, 2 and 3, together with compound i52;
Figure 2 and Table 2) were used in its neutral protonation state.
Assignment of the atom types and charge calculations were
performed by using Sybyl 7.2. A conformational analysis was first
performed to all compounds to be docked by use of the program
Macromodel (24) and the Monte Carlo methodology. The parameters
given to Macromodel were set to default with some exceptions. The
force field selected was OPLS-AA. GS/SA solvation model was
selected. The program was set to explore trough 1000 steps modifying
three torsional angles each step. The limit of acceptance was set
to 50 kJ/mol above the instant minimum found. The minimization
method selected was conjugated gradient. The convergence RMS was
set to a limit of 2 Å. The criteria of minimization convergence was
set to 0.05 kJ/ Å-mol.
TABLE 3. Different entries of the MMP-2 deposited in the Protein Data Bank
Pdb Information Experimental Method Reference
Code  and Resolution
1ck7 Full length protein X-Ray (2.80 Å) (35)
1eak Catalytic domain
 (inactive and mutant) X-Ray (2.66 Å) (36)
1qib Catalytic domain with the
inhibitor Batimastat X-Ray (2.80 Å) (37)
(not resolved)
1gxd ProMMP-2/TIMP-2 complex
(inactive) X-Ray (3.10 Å) (38)
1hov Catalytic domain with
inhibitor SC-74020 (i52) NMR (11 models) (32)
complex
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FIGURE 2. Chemical structure of compound i52.
Superimposition
All the conformers resulting from the conformational search
were then superimposed to the ligand i52 (Figure 2) present in
the 1hov structure. This ligand was previously submitted to the
same conformational search analysis and followed the same
superimposition procedure in order to validate the methodology.
The criteria selected for the superimposition was the maximum
number of atoms fitted using the CSR program (25). Only the
conformers with the higher number of atoms fitted were selected for
the docking studies. The RMSD average of the selected ligands by
superimposition to i52 was 0.9345 ± 0.2543.
Docking
The docking studies were carried out using AutoDock 3.0 program
(26). Two different parameter sets for the zinc ion were used: the
implicit parameters for the zinc inside AutoDock program, and the
Stote and colleagues (27) which means r = 1.1 Å, ε = 0.25 kcal/mol
and a formal charge of +2e. Very slight differences were observed
within both protocols (data not shown).
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The Lamarckian Genetic Algorithm (LGA) was used as the search
engine. The active site was defined using AutoGrid. The grid size was
set to 128 x 60 x 60 points with a grid spacing of 0.375 Å centered
on the catalytic zinc of each 1hov model. Step sizes of 2 Å for
translation and 60º for rotation were chosen. The maximum number
of energy evaluations was set to 250000. For each of the 100
independent runs, a maximum number of 27000 LGA operations
were generated on a single population of 100 individuals. The
compounds were studied with no restraints between the ZBG and
the zinc atom. Other variables were set by using AutoDock Tools
(ADT) (26).
Perl-based Filter
A perl program was developed in order to classify the compounds
into three different categories depending on the coordination with
the zinc ion: trigonal bypiramide coordination, square-based
pyramide coordination and no coordinating compound using the
mean atom distance and angles displacement published by Alberts
and colleagues (Figure 3) (28).
Biological Assays
The MMP-2 Colorimetric Drug Discovery Kit (purchased from
Biomol International, Lp., Exeter, UK) was selected for the biological
evaluation of MMP-2 inhibition by the selected compounds 1n, 2m
and 2n. Inhibition assays were carried out in duplicate at four
different concentrations (100 μM, 25 μM, 6.5 μM and 3.25 μM). The
inhibitor NNGH (29) was also included as a prototypic control
inhibitor. A commercially available negative control, with reported
no MMP inhibitory activity, was treated similarly (30).
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FIGURE 3. Different geometries for the coordination of the Zn2+ ion found in
the bibliography for proteases zinc-dependent. MMPIs are found to coordinate
by square-based pyramidal or trigonal bipyramidal geometry (19, 28). Zinc is the
center ion and the donnor atoms are in coordinating position. Coordinating atoms
in MMP are 3 His and one or two atoms of the ligand.
Tetrahedrical
coordination
Square-based
pyramidal coordination
Trigonal bipyramidal
coordination
Octahedrical
coordination
RESULTS
MMP-2 Selection
Five structures corresponding to MMP-2 subtype metalloproteinase
are found in the Brookhaven Protein Data Bank (31), as shown in
Table 3. No X-ray structures of MMP-2-Inhibitor complexes have been
reported so far, and the PDB codes 1ck7 and 1qib corresponding to
active MMP-2 exhibit low resolution values (2.80 Å). Only the NMR
structure with PDB code 1hov corresponds to a complex with a
hydroxamic acid inhibitor (i52, see Figure 2). For this reason it was
considered as the host structure for docking purposes. The eleven
models that contain the PDB 1hov (M1, M2,… M11) were considered
in the subsequent docking studies, as it would allow to reflect the
dynamic nature of MMP-2 in an aqueous environment.
Conformational Search and Docking
The series of compounds is characterized by the hydrocarbonated
chain that joins the two potential ZBG, which means, that all
compounds have at least 10 rotatable bonds. A torsional problem has
been reported finding good docked hits when the rotatable
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bonds of the ligands were more than 10 (19). Trying to minimize
this difficulty, all compounds (1a to 3n) were submitted to a
conformational search using Macromodel in order to get the
maximum conformational diversity. The conformational search of all
compounds led to very similar conformers in terms of energy and, in
general, non-extended conformations as the most stable ones.
AutoDock was selected as the program to be used in the docking
procedures. The selection was based on its wide use in similar cases
described in the literature. In order to validate AutoDock as a docking
tool, the first ligand that followed this protocol (conformational
search, superimposition and docking) was compound i52 (32), the
ligand present in 1hov structure in the complex with MMP-2.
AutoDock was able to reproduce the NMR results and to predict the
conformation in which i52 is bound inside the MMP-2 active site.
Data Analysis
A perl-based program was developed to filter the vasta amount
of data generated. Distances and the angles between the ZBG, the
three catalytic histidines and the zinc ion, were calculated from
the docking results. Further analysis of the data allowed the
identification of the docked geometries with the adequate
coordination. For the MMP family, the pentacoordinated zinc has
been shown to be the most frequent coordination state (19), with
two possible geometries: trigonal bypiramide or square-based
pyramide. Both possibilities were scanned by the perl filter. The
analysis was set to a first limit of 2.53 Å of distance, and 0º of
variation from the angles described in the literature (28). The
distance of 2.53 Å is the maximum reported distance between a
coordinating atom and the Zn2+ reported for MMPs.
Following this protocol, 98 conformers were found to be able to
coordinate Zn ion inside any of the 11 NMR models. Table 4 shows
the ability of these compounds to bind the MMP-2 active site.
Complex MMP-2:i52 was submitted to the same perl filter leading to
only two positive hits. A detailed analysis of the 11 NMR complex
models, led to the observation that only models 1 and 3 fullfilled the
requiered distance and angle restrictions found in the literature for
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MMP-2 inhibitors should not only be good zinc coordinating
agents, but also they should interact with key amino acids which are
crucial for the ligand binding (7, 33, 34). Taking into account this
information, the 98 positive docking hits were visually inspected
displaying the residues within 4 Å around the ligand. Thus, residues
belonging to S1, S2, S3, S1’, S2’, and S3’ subsites were analyzed
looking for putative interactions with each of the 98 conformers
(data not shown). Compound i52 was included in this analysis
to provide a reference for contacts with the residues belonging to
the different subsites. Interactions with S1’ residues were used as
a filter to select 27 docking conformers, belonging to 15 different
zinc coordination. A positive hit for one compound is considered
when at least one of its conformers is able to coordinate the zinc ion,
for one of the NMR models, taking into account the distances and
angles restrictions described above. Eleven is then the maximum of
possible positive hits for each compound. Using this procedure, we
found 59 positive hits within a maximun of 264 (24 compounds * 11
models). AutoDock predicted that all compounds were able to
coordinate the zinc atom at least in one of the eleven NMR models
and at least in one conformation, except compound 1g.
TABLE 4. Number of positive hits through the eleven NMR models resolved for
1hov in Protein Data Bank for each docked compound
Number Number Number Number
Compound of Compound of Compound of Compound of
positive positive positive positive
hits hits hits hits
1a 1 1j 3 2j 5 3j 5
1b 2 1k 2 2k 3 3k 3
1c 1 1l 3 2l 2 3l 2
1d 2 1m 3 2m 5 3m 1
1e 2 1n 4 2n 2 3n 3
1f 1
1g 0 i52 2
1h 2
1i 2
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FIGURE 4. Representation of the pattern of interaction between the 27
docking conformers analyzed and the amino acids of S1’ subpocket of
MMP-2 (position in the energy ranking in Autodock is given in parenthesis).
Conserved amino acids are colored yellow. No conserved amino acids are colored
blue. Amino acids that are reported to be able to establish hydrogen bonds are
colored green. Compound i52 from the PDB 1hov is also included as a reference.
compounds, as those which better fulfilled the interactions’ pattern
exhibited by i52. These results are displayed in Figure 4.
FIGURE 5. Docking result for 1n (blue) in comparison with i52 (orange)
resolved by NMR. 1n is able to coordinate Zn2+ occupying the same subistes
as i52.
Compounds 1n, 2m and 2n were the most promising candidates
to perform MMP-2 inhibition assays, because they showed a similar
S1’ sub-site contacts pattern to that of i52. These interactions
included unique residues to MMP-2, as Ala139, Thr 143, Tyr144, and
Thr145, and were not observed for the other docking conformers.
Figure 5 shows the resulting docking for 1n (blue) superimposed to
i52 (orange).
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Biological Assays
According to the computational work, preliminary MMP-2
inhibition assays were carried out in duplicate for compounds 1n,
2m and 2n. Only 1n showed an interesting MMP-2 inhibitory activity.
Preliminary data show the decrease of the MMP-2 activity in the
presence of 1n, suggesting that this compound may be a promising
MMP-2 inhibitor. Unexpectedly, compounds 2m and 2n did not show
detectable MMP-2 inhibition. It has to be taken into account that
these two compounds are synthesis intermediates, so their character
as positive/negative AM modulators has not been determined yet.
AM affinity studies are currently in progress.
CONCLUSION
In this work we have carried out a theoretical study making
use of molecular mechanics, docking and molecular dynamics
techniques with the aim of demonstrating that positive modulators
of AM, may be acting as MMP-2 inhibitors as a possible mechanism
of action. This hypothesis has proven to be correct, according
to our theoretical studies, since almost all compounds evaluated
are able to bind MMP-2 in some of the conformations considered,
by chelating the zinc ion and interacting with key aminoacids in
the binding site of this enzyme. This ability and versatility to
coordinate Zn2+ ion seems to be a prominent feature of this family
of compounds not described before, to the best of our knowledge.
Additionally, the moderated electron donor character of the aryloxi
oxygen and the heterocyclic nitrogen, makes this family of
compounds an excellent alternative ZBG to hydroxamic acids, where
the pronounced zinc chelating properties may cause lack of
specificity. Biological evaluation of MMP-2 inhibition by some
selected compounds, selected according to the previous theoretical
work, has shown that compound 1n possesses an interesting
inhibitory activity.
Interestingly, the ZBG contained in this compound, does not
appear in any of the many MMP2 inhibitors reported in the
bibliography. This finding opens up an unexplored structural field
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for the search of MMP-2 inhibitors with interest for the treatment of
many inflammatory, malignant, and degenerative diseases.
ACKNOWLEDGMENT
This work was supported by the Spanish Ministry of Education
(SAF2005-02608). S. M.-S. thanks Ministerio de Educación y Ciencia
for a Ramón y Cajal contract. Grant to M. A. G. from Comunidad
Autónoma de Madrid is also acknowledged.
BIBLIOGRAPHY
(1) MARTÍNEZ, A.; OH, H. R.; UNSWORTH, E. J.; BREGONZIO, C.; SAAVEDRA, J. M.;
STETLER-STEVENSON, W. and CUTTITTA, F. (2004): Matrix metalloproteinase-2
cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.
Biochem. J. 383: 1-6.
(2) MARTÍNEZ, A.; JULIAN, M.; BREGONZIO, C.; NOTARI, L.; MOODY, T. and CUTTITA,
F. (2004): Identification of vasoactive non-peptidic positive and negative
modulators of adrenomedullin using a neutralizing antibody-based screening
strategy. Endocrinology 145: 3858-3865.
(3) JOHNSON, L. L.; DYER, R. and HUPE, D. J. (1998): Matrix metalloproteinases.
Curr. Opin. Chem. Biol. 2: 466-471.
(4) PIRARD, B. and MATTER, H. (2006): Matrix metalloproteinase target family
landscape: a chemometrical approach to ligand selectivity based on protein
binding site analysis. J. Med. Chem. 49: 51-69.
(5) BABINE, R. E. and BENDER, S. L. (1997): Molecular Recognition of Protein-
Ligand Complexes: Applications to Drug Design. Chem. Rev. 97: 1359-1472.
(6) VERMA, R. P. and HANSCH, C. (2007): Matrix metalloproteinases (MMPs):
Chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 15: 2223-
2268.
(7) WHITTAKER, M.; FLOYD, C. D.; BROWN, P. and GEARING, A. J. (1999): Design and
therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev.
99: 2735-2776.
(8) LOVEJOY, B.; HASSELL, A. M.; LUTHER, M. A.; WEIGL, D. and JORDAN, S. R. (1994):
Crystal structures of recombinant 19-kDa human fibroblast collagenase
complexed to itself. Biochemistry (Mosc). 33: 8207-8217.
(9) SCOZZAFAVA, A. and SUPURAN, C. T. (2000): Protease inhibitors: Synthesis
of potent bacterial collagenase and matrix metalloproteinase inhibitors
incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J. Med.
Chem. 43: 1858-1865.
MARIO A. GARCÍA Y COLS. AN. R. ACAD. NAC. FARM.
722
(10) SAGHATELIAN, A.; JESSANI, N.; JOSEPH, A.; HUMPHREY, M. and CRAVATT, B. F. (2004):
Activity-based probes for the proteomic profiling of metalloproteases. Proc.
Natl. Acad. Sci. U. S. A. 101: 10000-10005.
(11) RAO, B. G. (2005): Recent developments in the design of specific Matrix
Metalloproteinase inhibitors aided by structural and computational studies.
Curr. Pharm. Des. 11: 295-322.
(12) WYNN, R. L. (1999): Latest FDA approvals for dentistry. Gen. Dent. 47: 19-22.
(13) BROWN, S.; BERNARDO, M. M.; LI, Z. H.; KOTRA, L. P.; TANAKA, Y.; FRIDMAN, R.
and MOBASHERY, S. (2000): Potent and selective mechanism-based inhibition
of gelatinases. J. Am. Chem. Soc. 122: 6799-6800.
(14) BROWNER, M. F.; SMITH, W. W. and CASTELHANO, A. L. (1995): Matrilysin-
inhibitor complexes: common themes among metalloproteases. Biochemistry
(Mosc). 34: 6602-6610.
(15) SCOZZAFAVA, A. and SUPURAN, C. T. (2000): Carbonic anhydrase and matrix
metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with
MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II,
and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med.
Chem. 43: 3677-3687.
(16) MICHAELIDES, M. R.; DELLARIA, J. F.; GONG, J.; HOLMS, J. H.; BOUSKA, J. J.;
STACEY, J.; WADA, C. K.; HEYMAN, H. R.; CURTIN, M. L.; GUO, Y.; GOODFELLOW,
C. L.; ELMORE, I. B.; ALBERT, D. H.; MAGOC, T. J.; MARCOTTE, P. A.; MORGAN, D.
W. and DAVIDSEN, S. K. (2001): Biaryl ether retrohydroxamates as potent,
long-lived, orally bioavailable MMP inhibitors. Bioorg. Med. Chem. Lett. 11:
1553-1556.
(17) KIKUCHI, K.; KOMATSU, K. and NAGANO, T. (2004): Zinc sensing for cellular
application. Curr. Opin. Chem. Biol. 8: 182-191.
(18) ONARAN, M. B.; COMEAU, A. B. and SETO, C. T. (2005): Squaric acid-based
peptidic inhibitors of matrix metalloprotease-1. J. Org. Chem. 70: 10792-
10802.
(19) HU, X.; BALAZ, S. and SHELVER, W. H. (2004): A practical approach to docking
of zinc metalloproteinase inhibitors. J. Mol. Graph. Model. 22: 293-307.
(20) SKILES, J. W.; GONNELLA, N. C. and JENG, A. Y. (2001): The design, structure,
and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med.
Chem. 8: 425-474.
(21) KITAMURA, K.; KANGAWA, K.; KAWAMOTO, M.; ICHIKI, Y.; NAKAMURA, S.; MATSUO, H.
and ETO, T. (1993): Adrenomedullin: a novel hypotensive peptide isolated
from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192: 553-
560.
(22) GARCÍA, M. A.; MARTÍN-SANTAMARÍA, S.; CACHO, M.; DE LA LLAVE, F. M.; JULIAN,
M.; MARTÍNEZ, A.; DE PASCUAL-TERESA, B. and RAMOS, A. (2005): Synthesis,
biological evaluation, and three-dimensional quantitative structure-activity
relationship study of small-molecule positive modulators of adrenomedullin.
J. Med. Chem. 48: 4068-4075.
(23) SYBYL, version 7.2.; Tripos.: St. Louis, Missouri, 1999.
(24) MOHAMADI, F.; RICHARDS, N. G. J.; GUIDA, W. C.; LISKAMP, R.; LIPTON, M.;
CAUFIELD, C.; CHANG, G.; HENDRICKSON, T. and STILL, W. C. (1990): MacroModel
VOL. 73 (3), 703-746, 2007 ARE ADRENOMEDULLIN POSITIVE MODULATORS NOVEL...
723
- An Integrated Software System for Modeling Organic and Bioorganic
Molecules Using Molecular Mechanics. J. Comput. Chem. 11: 440-467.
(25) PETITJEAN, M. (1998): Interactive maximal common 3D substructure searching
with the combined SDM/RMS algorithm. Computers & Chemistry 22: 463-
465.
(26) MORRIS, G. M.; GOODSELL, D. S.; HALLIDAY, R. S.; HUEY, R.; HART, W. E.; BELEW,
R. K. and OLOSN, A. J. (1998): Automated docking using a Lamarckian genetic
algorith and an empirical binding free energy function. J. Comput. Chem. 19:
1639-1662.
(27) STOTE, R. H. and KARPLUS, M. (1995): Zinc binding in proteins and solution:
a simple but accurate nonbonded representation. Proteins 23: 12-31.
(28) ALBERTS, I. L.; NADASSY, K. and WODAK, S. J. (1998): Analysis of zinc binding
sites in protein crystal structures. Protein Sci. 7: 1700-1716.
(29) MACPHERSON, L. J.; BAYBURT, E. K.; CAPPARELLI, M. P.; CARROLL, B. J.; GOLDSTEIN,
R.; JUSTICE, M. R.; ZHU, L.; HU, S.; MELTON, R. A.; FRYER, L.; GOLDBERG, R. L.;
DOUGHTY, J. R.; SPIRITO, S.; BLANCUZZI, V.; WILSON, D.; O’BYRNE, E. M.; GANU, V.
and PARKER, D. T. (1997): Discovery of CGS 27023A, a non-peptidic, potent,
and orally active stromelysin inhibitor that blocks cartilage degradation in
rabbits. J. Med. Chem. 40: 2525-2532.
(30) DANIELS, J. T.; SCHULTZ, G. S.; BLALOCK, T. D.; GARRETT, Q.; GROTENDORST, G. R.;
DEAN, N. M. and KHAW, P. T. (2003): Mediation of transforming growth factor-
beta(1)-stimulated matrix contraction by fibroblasts: a role for connective
tissue growth factor in contractile scarring. Am. J. Pathol. 163: 2043-52.
(31) BERMAN, H. M.; WESTBROOK, J.; FENG, Z.; GILLILAND, G.; BHAT, T. N.; WEISSIG, H.;
SHINDYALOV, I. N. and BOURNE, P. E. (2000): The Protein Data Bank. Nucleic
Acids Res. 28: 235-242.
(32) FENG, Y. Q.; LIKOS, J. J.; ZHU, L. M.; WOODWARD, H.; MUNIE, G.; MCDONALD,
J. J.; STEVENS, A. M.; HOWARD, C. P.; DE CRESCENZO, G. A.; WELSCH, D.; SHIEH,
H. S. and STALLINGS, W. C. (2002): Solution structure and backbone dynamics
of the catalytic domain of matrix metalloproteinase-2 complexed with a
hydroxamic acid inhibitor. Biochim. Biophys. Acta 1598: 10-23.
(33) LUKACOVA, V.; ZHANG, Y.; MACKOV, M.; BARICIC, P.; RAHA, S.; CALVO, J. A.
and BALAZ, S. (2004): Similarity of binding sites of human matrix
metalloproteinases. J. Biol. Chem. 279: 14194-14200.
(34) TAKAHASHI, K.; IKURA, M.; HABASHITA, H.; NISHIZAKI, M.; SUGIURA, T.; YAMAMOTO,
S.; NAKATANI, S.; OGAWA, K.; OHNO, H.; NAKAI, H. and TODA, M. (2005): Novel
matrix metalloproteinase inhibitors: Generation of lead compounds by the in
silico fragment-based approach. Bioorg. Med. Chem. 13: 4527-4543.
(35) MORGUNOVA, E.; TUUTTILA, A.; BERGMANN, U.; ISUPOV, M.; LINDQVIST, Y.;
SCHNEIDER, G. and TRYGGVASON, K. (1999) Structure of human pro-matrix
metalloproteinase-2: Activation mechanism revealed. Science 284: 1667-1670.
(36) BERGMANN, U.; TUUTTILA, A.; MORGUNOVA, E. and TRYGGVASON, K. Crystal
Structure of Human Mmp-2. (to be published).
(37) DHANARAJ, V.; WILLIAMS, M. G.; YE, Q.; MOLINA, F.; JOHNSON, L. L.; ORTWINE, D.
F.; PAVLOVSKY, A.; RUBIN, J. R.; SKEEAN, R. W.; WHITE, A. D.; HUMBLET, C.; HUPE,
D. J. and BLUNDELL, T. L. (1999): X-ray Structure of Gelatinase A Catalytic
MARIO A. GARCÍA Y COLS. AN. R. ACAD. NAC. FARM.
724
Domain Complexed with a Hydroxamate Inhibitor. Croatica Chemica Acta
72: 575-591.
(38) MORGUNOVA, E.; TUUTTILA, A.; BERGMANN, U. and TRYGGVASON, K. (2002):
Structural insight into the complex formation of latent matrix
metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl.
Acad. Sci. U. S. A. 99: 7414-7419.
